ICU Medical ( (ICUI) ) has released its Q1 earnings. Here is a breakdown of the information ICU Medical presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ICU Medical, Inc. is a global leader in the development, manufacture, and sale of innovative medical products, primarily focusing on infusion systems, consumables, and critical care products for various healthcare settings.
In its first quarter of 2025, ICU Medical reported a revenue increase to $604.7 million, up from $566.7 million in the same period last year, reflecting growth across its product lines. The company also saw improvements in its GAAP gross profit and gross margin, despite reporting a net loss.
Key financial highlights include a GAAP gross profit of $210.1 million and a gross margin of 35%, both up from the previous year. The company reduced its GAAP net loss to $15.5 million from $39.5 million in the prior year. Adjusted diluted earnings per share rose significantly to $1.72 from $0.96, and adjusted EBITDA increased to $99.4 million from $78.8 million.
The revenue growth was driven by increases in the Consumables, Infusion Systems, and Vital Care product lines. Notably, the Consumables line saw a $22.1 million increase, while Infusion Systems and Vital Care grew by $9.0 million and $6.9 million, respectively.
Looking ahead, ICU Medical’s management remains optimistic about maintaining its growth trajectory, aligning with their expectations for the year. The company continues to focus on delivering quality and innovation to its clinical customers worldwide.